NASDAQ:CDT Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis $0.10 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Conduit Pharmaceuticals Stock (NASDAQ:CDT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CDT alerts:Sign Up Key Stats Today's Range$0.10▼$0.1150-Day Range$0.09▼$0.1452-Week Range$0.08▼$7.83Volume24.06 million shsAverage Volume9.55 million shsMarket Capitalization$9.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Receive CDT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CDT Stock News HeadlinesConduit Pharmaceuticals receives further patent approval for AZD1656November 21 at 10:27 PM | markets.businessinsider.comWhat's Going On With Conduit Pharmaceuticals Shares Today?November 21 at 10:27 PM | benzinga.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.November 23, 2024 | Weiss Ratings (Ad)Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune DisordersNovember 21 at 7:30 AM | globenewswire.comConduit Pharmaceuticals Announces Leadership Changes and Bylaws UpdateNovember 20 at 9:39 AM | markets.businessinsider.comConduit Pharmaceuticals Announces Appointment of Simon Fry to Board of DirectorsNovember 19, 2024 | globenewswire.comConduit Pharmaceuticals announces new addition to autoimmune pipelineNovember 5, 2024 | markets.businessinsider.comConduit Pharmaceuticals Announces New Addition to its Autoimmune PipelineNovember 4, 2024 | globenewswire.comSee More Headlines CDT Stock Analysis - Frequently Asked Questions How have CDT shares performed this year? Conduit Pharmaceuticals' stock was trading at $4.55 at the beginning of 2024. Since then, CDT stock has decreased by 97.7% and is now trading at $0.1040. View the best growth stocks for 2024 here. How do I buy shares of Conduit Pharmaceuticals? Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Conduit Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN). Company Calendar Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDT Previous SymbolNASDAQ:CDT CUSIPN/A CIK1896212 Webwww.conduitpharma.com Phone760-471-8536FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-320.58% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-1.16Miscellaneous Outstanding Shares96,000,000Free Float62,653,000Market Cap$9.98 million OptionableNot Optionable Beta2.14 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:CDT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.